Article
[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1].
The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi - 1 Mar 2016
Park Sang Hoon
Abstract excerpt
The introduction of direct-acting antiviral agents (DAAs) has markedly improved the sustained virological response (SVR) rates in patients with chronic hepatitis C. Currently, four classes of DAAs targeting three HCV proteins (NS3, NS5A, and NS5B) have been approved for treatment in many countries. Since drugs show advantages and disadvantages, use of a combination of two or more DAAs with different targets or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.